Synlogic to be Delisted from Nasdaq, Shares Moving to OTC Market
summarizeSummary
Synlogic, Inc. announced its common stock will be suspended from Nasdaq trading on January 21, 2026, after the company withdrew its appeal against a 'public shell' determination, with plans to move to the OTC Markets.
check_boxKey Events
-
Nasdaq Delisting Confirmed
Synlogic's common stock will be suspended from Nasdaq trading at the open of business on January 21, 2026.
-
Voluntary Withdrawal of Appeal
The company withdrew its request for a hearing with Nasdaq's Hearings Panel on January 16, 2026, deciding not to pursue continued listing.
-
Transition to OTC Markets
Synlogic expects its shares to be quoted on the OTC Markets Group, Inc. following delisting from Nasdaq.
-
Previous 'Public Shell' Determination
Nasdaq had previously notified the company of its belief that Synlogic is a 'public shell,' which initiated the delisting process.
auto_awesomeAnalysis
Synlogic, Inc.'s decision to withdraw its appeal against Nasdaq's 'public shell' determination and proceed with delisting is a critical negative event. Moving from Nasdaq to the OTC Markets typically results in significantly reduced liquidity, decreased investor visibility, and a potential decline in institutional interest. While the company states business operations will not be affected and it will remain a reporting company, the transition to OTC generally makes it more challenging to attract new capital and maintain investor confidence. This event fundamentally alters the trading environment for the stock, which is already near its 52-week low, and investors should anticipate increased volatility and trading risks.
At the time of this filing, SYBX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.90 to $1.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.